Sign In
Buy CSU
$33.30
+0 (+0%)
At Close: Jul 20, 2022
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled di
Constellation Software Inc. Announces Conference Call
05:03pm, Friday, 26'th Sep 2025
TORONTO, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or “CSI”) announced today its President, Mark Miller, and its Chief Financial Officer, Jamal
Constellation Software Inc. - Special Call
03:23pm, Monday, 22'nd Sep 2025
Constellation Software Inc. - Special Call Company Participants Mark Leonard - Founder, President & Director Paul McFeeters Conference Call Participants Thanos Moschopoulos - BMO Capital Markets Equit
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
12:29am, Monday, 22'nd Sep 2025
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU
Constellation Software Inc. Announces Conference Call to Discuss AI's Impact on Software Businesses
11:17am, Tuesday, 16'th Sep 2025
TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or “CSI”) announced today it will host a live shareholder question and answer audio webcast
Constellation Software Inc. Announces Results for the Second Quarter Ended June 30, 2025 and Declares Quarterly Dividend
05:00pm, Friday, 08'th Aug 2025
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30,
Constellation Software Inc. Announces Release Date for Second Quarter Results
05:50pm, Monday, 14'th Jul 2025
TORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its second quarter results on August 8, 2025.
Constellation Software Inc. Announces Results for the First Quarter Ended March 31, 2025 and Declares Quarterly Dividend
05:01pm, Monday, 12'th May 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the first quarter ended March 31, 2
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
11:15am, Friday, 18'th Apr 2025
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and
Constellation Software Inc. Announces Release Date for First Quarter Results
06:15pm, Monday, 14'th Apr 2025
TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its first quarter results on May 12, 2025.
Constellation Software: Head For The Stars With This Stellar Compounder
04:26am, Monday, 07'th Apr 2025
Constellation Software has delivered a 34% annualized return since its 2006 IPO, driven by its strategic acquisition of Vertical Market Software businesses. Founder Mark Leonard's long-term focus and
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase II
